Avenue Therapeutics May Offer Shares Of Common Stock Having Offering Price Of Up To $3.9M From Time To Time Through Agent
- SEC Filing
- SEC Filing
10-Q - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
S-8 - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)
Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(15.40) per share which missed the analyst consensus estimate of $(9.00) by 71.11 percent. This is a 85.01 percent increase over losses of $(102.75) per share from the same period last year.
- SEC Filing
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Location: New YorkFormat: Company Presentation and 1x1 Meetings Lake Street Capital Markets BIG8 ConferenceDate: Thursday, September 12, 2024Location: New YorkFormat: 1x1 Meetings The H.C. Wainwright
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 MIAMI, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the second quarter ended J
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds from a May 2024 warrant exercise transaction - MIAMI, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2024. "We continue to make meaningful progress advancing our pipeline of innovative treatments fo
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi
SC 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
SC 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)
MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and chronic kidney disease, today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors. Lindsay A. Rosenwald, M.D., Fortress' Chairman and Chief Executive Officer and Board Member of Urica, said, "We ar